Plans to seek regulatory approval to commence a Phase III trial in the US and Canada
Sustained Therapeutics Inc., a clinical-stage therapeutics company developing a non-opioid treatment for pain, announced positive results from its Phase 2 clinical trial evaluating ST-01, the Company’s novel sustained-release drug.
ST-01 was designed to deliver sustained, localized non-opioid pain relief for approximately 28 days from a single injection, addressing a major unmet need for patients with limited effective long-term treatment options.
The trial was focused on Chronic Scrotal Pain (CSP), a debilitating condition affecting over 5 million men in North America with 700,000 new cases each year.
Current treatment options for CSP are limited and often ineffective, ranging from analgesics such as ibuprofen to invasive surgical interventions, with approximately 15% of patients ultimately undergoing surgery. In a recent survey of urologists treating CSP, 80% reported that ST-01 addresses a significant unmet clinical need, citing its potential impact on patient care and its ease of administration, which requires no specialized training.
This Phase 2 trial evaluated the safety and efficacy of repeat monthly dosing of ST-01 compared with standard of care therapy with lidocaine alone. The study received regulatory clearance from Health Canada and was conducted across eight clinical sites in Canada, enrolling a total of 63 patients. The trial was designed to reflect real-world treatment patterns and to assess the feasibility and potential benefit of repeated administration.
Results demonstrated that ST-01 was safe and effective delivering clinically meaningful reductions in pain that were sustained across repeated treatment cycles. The study met both its primary and secondary endpoints. Based on these results, Sustained Therapeutics plans to proceed to Phase 3 trials in Canada and the United States, subject to regulatory approval.
Many men suffering from chronic scrotal pain are in the prime of their lives and experience persistent, often debilitating pain that significantly impacts their quality of life. The exciting Phase 2 results reinforce our belief that ST-01 has the potential to reduce or even resolve pain over time with repeat treatment, offering patients a meaningful alternative to existing therapies.
said Dr. Martin Gleave, co-founder and Chief Medical Officer of Sustained Therapeutics.
The opioid epidemic continues to be one of the most pressing public health crises across North America, and far too often patients with long term chronic pain have few non-opioid options. There is an urgent need for effective, non-opioid alternatives that provide sustained pain relief without contributing to dependency.
said William Annett, CEO, Sustained Therapeutics.
Beyond chronic scrotal pain, Sustained Therapeutics is planning to conduct trials of ST-01 in other chronic pain indications with high unmet needs. These include Chronic Pelvic Pain (CPP), which afflicts about 14 million people in North America, trigeminal neuralgia, and post amputation or “phantom limb” pain.
In addition to ST-01 Sustained Therapeutics’ proprietary sustained-release drug delivery platform has also been customized for the delivery of other medications requiring localized, long-lasting therapy. A Phase 2/3 clinical trial of ST-02, a sustained release chemotherapy, is underway for Upper Tract Urothelial Carcinoma (UTUC), an orphan disease.
The Company has also developed ST-04 as a treatment for erectile dysfunction in the approximately 30% of men who do not respond to current standard of care ED medications. A Phase 2 study of ST-04 has received regulatory clearance from Health Canada and is projected to begin shortly.
One of the defining strengths of our platform is its versatility. While chronic neuropraxic pain disorders remain our lead program, these results further validate our approach and open the door to many small-molecule therapies.
Dr. Gleave added.
Based on the results of the Phase 2 study, Sustained Therapeutics is advancing ST-01 into its next stage of development and strengthening its leadership team to support continued clinical and corporate momentum.
For more information, read the original press release.
For more news from the world of long-acting therapeutics, sign up to the CELT's LONGEVITY mailing list here for regular updates.